Abstract
The aim of the present study, a multicentre trial of didanosine (ddI) compassionate use, was to identify factors associated with a better outcome in patients given ddI monotherapy. Enrolled were 1047 HIV-positive patients intolerant of and/or unresponsive to zidovudine (ZDV) therapy, with CD4+ cell counts of < 200/μl or AIDS. Didanosine was given at a dose of 250 mg b.i.d. (patients ≥ 60 kg) or 167 mg b.i.d. (patients < 60 kg). Clinical examinations and laboratory tests were performed every two months. Endpoints included death, the occurrence of a new AIDS-defining disease, or permanent discontinuation of ddI for a severe adverse event. At entry, the median CD41 cell count was 47/μl and the median duration of prior ZDV treatment 19 months; 446 patients (43%) were classified as having AIDS. Severe toxicity occurred in 143 subjects (14%); the frequency of pancreatitis was very low (0.2%), The benefit in terms of CD4+ cell counts was greater for patients whose counts exceeded 100/μl at entry and remained at this level until month 12 in those patients still receiving treatment. Death and/or new AIDS-defining events were observed in 374 cases (36%) over a median follow-up of eight months. AIDS dementia was observed in 11 patients (1 %). Multivariate analysis of survival without disease progression showed that the factors associated with a worse outcome include the severity of immunodepression, a diagnosis of AIDS at entry, and a history of both intolerance of and clinical resistance to ZDV. Surprisingly, the patients who had received previous prolonged treatment with ZDV had a better outcome. In conclusion, severely immunodepressed patients previously administered long-term monotherapy may receive a short-term benefit from being switched to another antiretroviral drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, and The AZT Collaborative Working Group: Efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. New England Journal of Medicine 1987, 317: 185–191.
Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Hardy WD, Soeiro R, Fischl MA, Barlett JG, Meringan TC, Hyslop NE, Richman DD, Valentine FT, Corey L, and the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases: Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. New England Journal of Medicine 1990, 322: 941–949.
Concorde Coordinating Committee: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343: 871–881.
Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George L, Gordin FM, Hawkes CA, Jensen PC, Klimas NG, Labriola AM, Lahart CJ, O'Brien WA, Ostr CN, Weinhold KJ, Wray NP, Zolla-Pazner SB, and the Veteran Affairs Cooperative Group on AIDS Treatment: A controlled trial of early versus late treatment with zidovudine in symptomatic human immuno-deficiency virus infection. New England Journal of Medicine 1992, 326: 437–443.
St.Clair MH, Hartigan PM, Andrews JC, Vavro CL, Simberkoff MS, Hamilton JD, and the VA Cooperative Study Group: Zidovudine resistance, syncytium-inducing phenotype and HIV disease progression in a case-controlled study. Journal of Acquired Immune Deficiency Syndromes 1993, 6: 891–897.
Kozal MJ, Merigan TC: HIV-resistance to dideoxynucleoside inhibitors. Infectious Diseases in Clinical Practice 1993, 2: 247–253.
Mayers DL: Zidovudine and other antiretroviral agents, including drug interactions and toxicities. Current Opinion in Infectious Diseases 1993; 6: 210–217.
Kahn J: New developments in the clinical use of didanosine. Journal of Acquired Immune Deficiency Syndromes 1993, 6, Supplement 1: 47–50.
Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou S-H, Brown M, Volberding PA, Crumpacker CS, Beall G, Sacks HS, Meringan TC, Beltangady M, Smaldone L, Dolin R, and the NIAID AIDS Clinical Trials Group: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. New England Journal of Medicine 1992, 327: 581–587.
Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA, and the Canadian HIV Trials Network Protocol 002 Study Group: Didanosine compared to continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. Annals of Internal Medicine 1995, 123: 561–571.
Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report 1987, 36, Supplement 1: 3–15.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958, 53: 457–481.
Cox DR: Regression models and life-tables. Journal of the Royal Statistical Society 1972, 34: 187–220.
Saah AJ, Hoover DR, He Y, Kinsley LA, Phair JR and the Multicenter AIDS Cohort Study: Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). Journal of Acquired Immune Deficiency Syndromes 1994, 7: 287–295.
Rothenberg R, Woefel M, Stoneburner R, Milberg J, Parker R, Truman B: Survival with the acquired immunodeficiency syndrome. New England Journal of Medicine 1987, 317: 1297–1302.
Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243: 1731–1734.
Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArtur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L, for the Bristol-Myers Squibb AI454-010 Study Group: Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Annals of Internal Medicine 1994, 120: 360–368.
Jablonowski H, Arasteh K, Staszewski S, Ruf B, Stellbrink H-J, Schrappe M, Stoehr A, Haase W, Schomaker U, von Eisenhart-Rothe B, Thomis J, Stille W, for the German ddI Trial Group: A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. AIDS 1995, 9: 463–469.
Pike IM, Nicaise C: The didanosine expanded access program: safety analysis. Clinical Infectious Diseases 1993, 16, Supplement: 63–68.
Montaner JS, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Weinberg M, Singer J, Schechter MT: Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program. Journal of Acquired Immune Deficiency Syndromes 1994, 7: 924–930.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Monforte, A.d., Musicco, M., Galli, M. et al. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Eur. J. Clin. Microbiol. Infect. Dis. 16, 135–142 (1997). https://doi.org/10.1007/BF01709472
Issue Date:
DOI: https://doi.org/10.1007/BF01709472